- AstraZeneca (NYSE:AZN) says that the U.S. government has closed a probe that investigated a major clinical trial used to win marketing approval for the company's new heart drug Brilinta.
- Following the DOJ's investigation into the study last October, doubts have ensued over the medicine's future success.
- AstraZeneca argues that Brilinta can bring in $3.5B in annual sales, although until now the drug has not made any record performance.
From other sites
Video at CNBC.com (Feb 11, 2015)
at CNBC.com (Feb 5, 2015)
at CNBC.com (Jan 14, 2015)
at CNBC.com (Jan 8, 2015)
at CNBC.com (Dec 29, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs